GSEA pointed to SP1 as the top transcription factor binding site for down-regulated DEGs; other differentially regulated pathways included neurodegenerative diseases, such as AD and Huntington disease, whereas up-regulated DEGs were found enriched for glutamate receptor activity and AKT1 knockdown pathways as expected. This evidence concerns the gene AKT1 and neurodegenerative disease.